Production & Sales - Launches

Exelixis’ collaborator Daiichi Sankyo launches MINNEBRO (Esaxerenone) tablets in Japan

Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has launched MINNEBRO (esaxerenone) tablets as a treatment for patients with hypertension in Japan.

Teva launches generic version of VESIcare (solifenacin succinate) tablets in US

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of a generic version of VESIcare (solifenacin succinate) Tablets, 5 mg and 10 mg, in the U.S.

Mundipharma launches Invokana and Vokanamet in Norway to treat type 2 diabetes

The Mundipharma network of independent associated companies has launched the type-2 diabetes mellitus (T2DM) treatments Invokana (canagliflozin) and Vokanamet (canagliflozin, metformin) in Norway.

Indivior introduces generic version of Suboxone opioid drug in US

The US affiliate of specialty pharmaceutical company Indivior has introduced an authorized generic version of Suboxone (buprenorphine and naloxone) sublingual film in the US.

Mayne Pharma launches Lexette (halobetasol propionate) foam 0.05% in US

Mayne Pharma Group, a specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals, has launched LEXETTE (halobetasol propionate) Foam 0.05% in the US.

GSK, Kyowa Hakko Kirin to commercialize anemia drug daprodustat in Japan

British drugmaker GlaxoSmithKline (GSK) has entered into a collaboration with Kyowa Hakko Kirin to commercialize daprodustat in Japan.

Nexus Pharmaceuticals gets FDA nod for Arsenic Trioxide injection in 10mg per 10mL vial

Nexus Pharmaceuticals has announced the immediate availability of Arsenic Trioxide Injection in 10mg per 10mL vial in the US.

Ferring launches Nocdurna in US to treat nocturia due to NP

Ferring Pharmaceuticals has announced the US launch of NOCDURNA (desmopressin acetate), a sublingual tablet indicated for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken more than two times per night to void.

GW announces US launch of cannabinoid medicine for seizures

GW Pharmaceuticals, along with its US subsidiary Greenwich Biosciences, has launched EPIDIOLEX (cannabidiol) oral solution CV in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older.